ES2294313T3 - Derivados de piridina como moduladores del receptor cb2. - Google Patents
Derivados de piridina como moduladores del receptor cb2. Download PDFInfo
- Publication number
- ES2294313T3 ES2294313T3 ES03750676T ES03750676T ES2294313T3 ES 2294313 T3 ES2294313 T3 ES 2294313T3 ES 03750676 T ES03750676 T ES 03750676T ES 03750676 T ES03750676 T ES 03750676T ES 2294313 T3 ES2294313 T3 ES 2294313T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- halogen
- group
- substituted
- nr8ar8b
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0222493.9A GB0222493D0 (en) | 2002-09-27 | 2002-09-27 | Compounds |
| GB0222493 | 2002-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2294313T3 true ES2294313T3 (es) | 2008-04-01 |
Family
ID=9944904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03750676T Expired - Lifetime ES2294313T3 (es) | 2002-09-27 | 2003-09-25 | Derivados de piridina como moduladores del receptor cb2. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20060240048A1 (enExample) |
| EP (1) | EP1565442B1 (enExample) |
| JP (1) | JP2006503845A (enExample) |
| KR (1) | KR20050071514A (enExample) |
| CN (1) | CN1703402A (enExample) |
| AR (1) | AR041395A1 (enExample) |
| AT (1) | ATE378317T1 (enExample) |
| AU (1) | AU2003268907A1 (enExample) |
| BR (1) | BR0314635A (enExample) |
| CA (1) | CA2500231A1 (enExample) |
| DE (1) | DE60317555T2 (enExample) |
| ES (1) | ES2294313T3 (enExample) |
| GB (1) | GB0222493D0 (enExample) |
| IS (1) | IS7809A (enExample) |
| MA (1) | MA27448A1 (enExample) |
| MX (1) | MXPA05003263A (enExample) |
| NO (1) | NO20052028L (enExample) |
| NZ (1) | NZ538943A (enExample) |
| PL (1) | PL375990A1 (enExample) |
| RU (1) | RU2005112752A (enExample) |
| TW (1) | TW200413321A (enExample) |
| WO (1) | WO2004029026A1 (enExample) |
| ZA (1) | ZA200502084B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1492784A4 (en) | 2002-03-28 | 2006-03-29 | Merck & Co Inc | SUBSTITUTED 2,3-DIPHENYLPYRIDINES |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| GB0402355D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| GB0402356D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| GB0402357D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| SE0401345D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine as scaffold |
| SE0401342D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| SE0401343D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine N oxide as scaffold |
| DK1753764T3 (da) | 2004-06-09 | 2009-02-16 | Glaxo Group Ltd | Pyrrolopyridin-derivater |
| BRPI0614272A2 (pt) * | 2005-08-09 | 2011-03-22 | Glaxo Group Ltd | derivados de imidazopiridinas como ligantes de receptores canabinóides |
| GB0519760D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
| JP2009536613A (ja) * | 2006-04-07 | 2009-10-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| WO2008040649A2 (en) * | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | Pyrazine-2-carboxamide derivatives as cb2 receptor modulators |
| WO2008063625A2 (en) * | 2006-11-20 | 2008-05-29 | Adolor Corporation | Pyridine compounds and methods of their use |
| BRPI0721268A2 (pt) * | 2007-02-22 | 2013-01-15 | Hemerus Medical Llc | dispositivo de filtragem de fluido biol[ogico, mÉtodo para processar um fluido biolàgico, sistema de filtragem de fluido biolàgico |
| WO2010084767A1 (en) * | 2009-01-22 | 2010-07-29 | Raqualia Pharma Inc. | N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity |
| CA2757188A1 (en) | 2009-03-30 | 2010-10-07 | Astellas Pharma Inc. | Pyrimidine compound |
| SG178867A1 (en) * | 2009-08-24 | 2012-04-27 | Neuralstem Inc | Synthesis of a neurostimulative piperazine |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| JP2013048962A (ja) * | 2012-12-12 | 2013-03-14 | Hemerus Medical Llc | 大容量の体液濾過装置 |
| WO2018055640A1 (en) * | 2016-09-22 | 2018-03-29 | Srf Limited | Process for the preparation of haloalkyl derivatives of nicotinic acid |
| MX2020012760A (es) | 2018-06-27 | 2021-03-25 | Hoffmann La Roche | Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2. |
| EP3995155A1 (en) | 2018-06-27 | 2022-05-11 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
| EP3814328B1 (en) | 2018-06-27 | 2026-03-11 | F. Hoffmann-La Roche AG | Novel azetidine-substituted pyridine compounds as inhibitors of cannabinoid receptor 2 |
| WO2020025574A1 (en) | 2018-08-03 | 2020-02-06 | Bayer Aktiengesellschaft | Process for the preparation of 6-(haloalkyl)-2-halo-5-acylpyridines and intermediates for this process |
| EP3666759A1 (en) | 2018-12-10 | 2020-06-17 | Bayer Aktiengesellschaft | Preparation of 6-halo-2-(haloalkyl)-3-acylpyridines and intermediates therefor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
-
2002
- 2002-09-27 GB GBGB0222493.9A patent/GB0222493D0/en not_active Ceased
-
2003
- 2003-09-25 PL PL03375990A patent/PL375990A1/xx not_active Application Discontinuation
- 2003-09-25 RU RU2005112752/04A patent/RU2005112752A/ru not_active Application Discontinuation
- 2003-09-25 ES ES03750676T patent/ES2294313T3/es not_active Expired - Lifetime
- 2003-09-25 NZ NZ538943A patent/NZ538943A/en unknown
- 2003-09-25 DE DE60317555T patent/DE60317555T2/de not_active Expired - Fee Related
- 2003-09-25 TW TW092126422A patent/TW200413321A/zh unknown
- 2003-09-25 CA CA002500231A patent/CA2500231A1/en not_active Abandoned
- 2003-09-25 AT AT03750676T patent/ATE378317T1/de not_active IP Right Cessation
- 2003-09-25 CN CNA038254727A patent/CN1703402A/zh active Pending
- 2003-09-25 US US10/528,613 patent/US20060240048A1/en not_active Abandoned
- 2003-09-25 BR BR0314635-9A patent/BR0314635A/pt not_active IP Right Cessation
- 2003-09-25 AR ARP030103499A patent/AR041395A1/es not_active Application Discontinuation
- 2003-09-25 JP JP2004539056A patent/JP2006503845A/ja not_active Withdrawn
- 2003-09-25 MX MXPA05003263A patent/MXPA05003263A/es unknown
- 2003-09-25 WO PCT/EP2003/010930 patent/WO2004029026A1/en not_active Ceased
- 2003-09-25 AU AU2003268907A patent/AU2003268907A1/en not_active Abandoned
- 2003-09-25 KR KR1020057005234A patent/KR20050071514A/ko not_active Withdrawn
- 2003-09-25 EP EP03750676A patent/EP1565442B1/en not_active Expired - Lifetime
-
2005
- 2005-03-11 ZA ZA200502084A patent/ZA200502084B/en unknown
- 2005-03-28 MA MA28176A patent/MA27448A1/fr unknown
- 2005-04-19 IS IS7809A patent/IS7809A/is unknown
- 2005-04-26 NO NO20052028A patent/NO20052028L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ538943A (en) | 2007-01-26 |
| EP1565442B1 (en) | 2007-11-14 |
| WO2004029026A1 (en) | 2004-04-08 |
| PL375990A1 (en) | 2005-12-12 |
| ATE378317T1 (de) | 2007-11-15 |
| TW200413321A (en) | 2004-08-01 |
| JP2006503845A (ja) | 2006-02-02 |
| AR041395A1 (es) | 2005-05-18 |
| DE60317555T2 (de) | 2008-10-23 |
| RU2005112752A (ru) | 2006-01-20 |
| CA2500231A1 (en) | 2004-04-08 |
| CN1703402A (zh) | 2005-11-30 |
| US20060240048A1 (en) | 2006-10-26 |
| MXPA05003263A (es) | 2005-07-05 |
| GB0222493D0 (en) | 2002-11-06 |
| DE60317555D1 (de) | 2007-12-27 |
| KR20050071514A (ko) | 2005-07-07 |
| ZA200502084B (en) | 2006-02-22 |
| NO20052028L (no) | 2005-06-03 |
| BR0314635A (pt) | 2005-08-02 |
| AU2003268907A1 (en) | 2004-04-19 |
| EP1565442A1 (en) | 2005-08-24 |
| MA27448A1 (fr) | 2005-07-01 |
| IS7809A (is) | 2005-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041395A1 (es) | Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR048778A1 (es) | Derivados de pirrolidinilo como inhibidores de 11-beta hidroxiesteroide deshidrogenasa | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| AR105340A2 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden | |
| BR0208455A (pt) | Derivados de glutaramida substituìda com n-fenpropilciclopentila como inibidores de nep para a fsad | |
| CO6190512A2 (es) | Compuestos antagonistas del receptor de glucagon composiciones que contienen dichos compuestos y procedimientos de uso | |
| ATE506354T1 (de) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
| ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| PE20110397A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
| AR058776A1 (es) | Compuesto de piridina condensado | |
| NO20070288L (no) | Nye alkynylderivater som modulatorer av metabotropiske glutamatreseptorer | |
| PE20160431A1 (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica | |
| AR066946A1 (es) | Compuestos heterociclicos antagonistas del receptor de histamina h3, y sus usos terapeuticos | |
| SV2009003157A (es) | Profarmaco de compuesto de cinamida | |
| CR8475A (es) | Fenilalanina-amidas sustituidas por benzoilo | |
| CO6190521A2 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa | |
| PE20061298A1 (es) | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c | |
| AR059329A1 (es) | Trialquilsilil-indoles, composiciones farmaceuticas y su utilizacion | |
| AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa | |
| IN2012DN03449A (enExample) | ||
| EA200970793A1 (ru) | Модуляторы рецепторов, активируемых пролифераторами пероксисом | |
| PE20091678A1 (es) | Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion-176 |